UltraSight
UltraSight develops FDA-cleared AI software that guides non-expert clinicians to acquire diagnostic-quality cardiac ultrasound images at the point of care, licensing the platform to health systems and partnering with ultrasound OEMs including Philips, Butterfly Network, and EchoNous.
- Company typePrivate
- Founded2018
- HeadquartersRehovot, Israel
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What UltraSight does
UltraSight is a digital health company developing FDA-cleared AI software that enables healthcare professionals without prior sonography experience to acquire diagnostic-quality cardiac ultrasound images at the point of care. Its core technology is a geometrical deep learning model that analyzes the ultrasound video stream in real time, predicts probe position relative to the heart, and renders 3D guidance instructions on screen; an image quality assessment module gates image capture only when diagnostic thresholds are met. The platform consists of the UltraSight Echosystem as the foundational environment, the AI Guidance Software as the primary capability, the Echo Stewardship Platform for multi-device enterprise workflow deployment, and PVAD IQ as a specialized module for microaxial flow pump position assessment in critical care.
The company is commercialized as B2B enterprise software to health systems, hospitals, and emergency departments, with the software designed as an accessory that pairs with compatible point-of-care ultrasound hardware from OEM partners including Philips Lumify, Butterfly Network, and EchoNous Kosmos. Revenue is generated through subscription-style enterprise licensing to healthcare institutions and through a licensing/royalty stream from a joint venture with SELVAS Healthcare that holds exclusive rights to distribute and commercialize the technology in Korea and Southeast Asia. Multi-jurisdictional regulatory approvals (FDA 510(k) across three clearances, CE Mark, UKCA, KFDA, Israeli AMAR) and clinical validation through studies at Mayo Clinic, Cleveland Clinic, Brigham and Women's, Stanford, University of Chicago, Aurora St. Luke's, and Jefferson Health underpin the commercial proposition, which targets the structural shortage of cardiac sonographers and the rising volume of echocardiographic exams.
UltraSight firmographics
Firmographics- Name
- UltraSight
- Legal name
- UltraSight® Inc.
- Website
- https://ultrasight.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- UltraSight develops FDA-cleared AI software that guides non-expert clinicians to acquire diagnostic-quality cardiac ultrasound images at the point of care, licensing the platform to health systems and partnering with ultrasound OEMs including Philips, Butterfly Network, and EchoNous.
- Ownership category
- akta.pro rank
UltraSight industry classification
Industry- Product category
- AI Cardiac Ultrasound Software
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Radiology AI, CAD & Advanced Visualization Software (HLAHABAJ)
- akta.pro secondary industries
- Medical Imaging AI (HDAAAEAH), Ultrasound & Echography Systems (HLAHABAD), AI Orchestration & Imaging Analytics Platforms (Model Management/Triage) (HLACALAG)
Keywords
Where UltraSight is headquartered
LocationHeadquarters
- HQ city
- Rehovot
- HQ country
- Israel
- HQ region
- Middle East
Offices2 records
Markets served
UltraSight business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
Revenue model
- AI-Guided Cardiac Ultrasound Software License: UltraSight's Real-Time Guidance software is designed as an accessory for point-of-care ultrasound systems and is licensed to healthcare institutions. The software pairs with compatible ultrasound devices to provide real-time guidance for cardiac image acquisition. Revenue is generated through licensing agreements with health systems, hospitals, and clinics that deploy the technology.
- Joint Venture Revenue - Asia Pacific: UltraSight has formed a joint venture with SELVAS Healthcare for Korea and Southeast Asia. SELVAS Healthcare has exclusive rights to distribute and commercialize UltraSight's AI cardiac ultrasound technology in Korea. This represents a licensing/royalty revenue stream from the joint venture arrangement.
Go-to-market motion3 records
Distribution channels4 records
Marketing channels6 records
UltraSight product offering
Product offeringCore offering
UltraSight develops AI-powered real-time guidance software that enables healthcare professionals without prior sonography experience to acquire diagnostic-quality cardiac ultrasound images at the point of care. The software analyzes the ultrasound video stream using geometric deep learning, predicts probe position relative to the heart, and provides 3D graphical guidance on probe maneuvering along with automated image quality assessment. It is designed as an accessory that pairs with compatible point-of-care ultrasound devices from partners such as Philips, Butterfly Network, and EchoNous, and is licensed to healthcare systems, hospitals, and OEMs worldwide.
Product overview
UltraSight offers a unified AI-powered cardiac ultrasound platform centered on its Real-Time Guidance software, which enables any healthcare professional to perform diagnostic-quality echocardiography regardless of sonography experience. The platform consists of the UltraSight Echosystem as the core AI environment, with the AI Guidance Software as the primary capability, the Echo Stewardship Platform for enterprise workflow management, and PVAD IQ as a specialized module for microaxial flow pump assessment in critical care settings. The software pairs with compatible point-of-care ultrasound devices including Philips Lumify, EchoNous Kosmos, and Butterfly Network hardware.
Differentiator
Problem solved
Functional benefit
Products and services
- UltraSight AI Guidance Software (Real-Time Guidance) Real-time AI guidance software that enables healthcare professionals without prior sonography experience to acquire diagnostic-quality cardiac ultrasound images at the point of care. The software analyzes the ultrasound video stream using geometric deep learning and provides 3D graphical guidance on probe maneuvering, then assesses image quality before allowing capture. Licensed to health systems, hospitals, and OEM ultrasound partners.
- Echo Stewardship Platform AI-guided enterprise workflow solution enabling health systems to scale focused cardiac ultrasound (FoCUS) using their existing multi-vendor ultrasound fleet. Provides multi-device compatibility and reduces variability at point of care while maintaining diagnostic quality.
- PVAD IQ FDA-cleared AI-powered software module that analyzes ultrasound images to monitor positioning of percutaneous ventricular assist devices (PVADs) in critical care. Automatically identifies the aortic valve plane and pump inlet on transthoracic echocardiography and calculates insertion depth in centimeters with a mean absolute error of 0.42 cm.
- UltraSight Echosystem Comprehensive AI-powered cardiac ultrasound platform encompassing the Real-Time Guidance software and supporting workflows for image acquisition, quality assessment, and clinical decision support across multiple care settings. Combines ultrasound video stream analysis with AI-guided probe maneuvering and image quality assessment.
Quantifiable outcome
- 93-100% of patient exams achieved sufficient diagnostic quality for clinical evaluation
- +7 more outcomes
Companies that use UltraSight
Customer profileNamed customers7 records
Segments4 records
Ideal customer profiles3 records
UltraSight technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
AI capability6 records
Feature6 records
UltraSight partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered minor and core.
- ARC (Sheba Medical Center Innovation Arm)minorUltraSight selected for ARC Landing Boston healthtech accelerator, providing access to clinical environments, regulatory support, strategic mentorship, and integration into ARC's global investment platforms.
- Jefferson HealthcoreClinical partnership with Jefferson Health in Philadelphia to conduct a study and pilot of UltraSight's AI-guided focused cardiac ultrasound technology. The pilot will evaluate whether AI-guided image acquisition can match traditional transthoracic echocardiography in rapidly assessing right-ventricular function in patients with suspected pulmonary embolism. Partially funded by Israel Innovation Authority through Jefferson-Israel 2025 Health Tech Pilot Program.
- Cleveland CliniccoreClinical study collaboration evaluating consonance between echocardiograms performed by non-sonographer healthcare professionals using UltraSight's AI Guidance Software versus experienced sonographers in patients with hypertrophic cardiomyopathy (HCM). Single-center pilot study enrolling up to 75 patients.
- Brigham and Women's HospitalcoreProspective clinical study enrolling 140 patients presenting to emergency department with symptoms such as syncope or TIA. Trial compares diagnostic capability between software-guided FoCUS and comprehensive transthoracic echocardiography (TTE), evaluating concordance rates and impact on patient disposition.
- American Society of Echocardiography (ASE)coreUltraSight selected as inaugural participant in ASE Accelerator Program, gaining access to product feedback, research validation opportunities, regulatory guidance, and commercialization strategies from industry experts. ASE is the world's largest cardiac subspecialty organization representing interests of physicians, sonographers, and scientists.
- Butterfly NetworkcoreUltraSight joined Butterfly Garden, an AI Marketplace launched by Butterfly Network. UltraSight aims to integrate and deploy its real-time AI guidance software on Butterfly's imaging platform for use with Butterfly's single-probe, whole-body handheld ultrasound system. The partnership targets expanding AI-guided cardiac imaging across point-of-care ultrasound devices.
- Mayo CliniccoreUltraSight and Mayo Clinic are jointly developing algorithms for analyzing and interpreting cardiac ultrasound images. Mayo Clinic has invested in UltraSight and provides access to researchers, clinicians, and data. The collaboration aims to create an end-to-end solution for point-of-care ultrasound enhanced by AI capabilities. Mayo Clinic is also conducting multiple clinical studies validating UltraSight's technology.
- SELVAS HealthcarecoreJoint venture between UltraSight and SELVAS Healthcare (subsidiary of SELVAS Group, Korean-based global digital healthcare company) for introducing UltraSight's technology in Asia, beginning with Korea and Southeast Asian market. SELVAS Healthcare has exclusive rights to distribute and commercialize UltraSight's AI cardiac ultrasound technology in Korea. KFDA approval was granted to SELVAS Invision.
- EchoNouscorePartnership to integrate UltraSight's real-time AI guidance software with EchoNous' KOSMOS handheld ultrasound device. The goal is enabling healthcare professionals with no prior sonography training to accurately conduct echocardiographic examinations, with focus on chronic cardiac patient monitoring closer to patients.
Scale indicators15 records
Recent moves7 records
Expansion highlights6 records
UltraSight competitors and assessment
Company assessmentDirect peers
- Butterfly Network: Handheld ultrasound hardware partner (Butterfly Garden) that also develops its own AI guidance capabilities. Direct overlap with UltraSight as both a distribution channel and a potential competitor in point-of-care AI cardiac ultrasound.
- Ultromics: AI echocardiography company focused on automated analysis and interpretation of cardiac ultrasound images. Targets similar cardiology customers and is pursuing FDA-cleared AI for echo interpretation, complementing UltraSight's acquisition-guidance focus.
- EchoNous: Handheld/portable ultrasound manufacturer (KOSMOS device) integrated with UltraSight's AI guidance software. Competes in the same point-of-care cardiac ultrasound category and could develop internal AI alternatives.
- Caption Health (GE HealthCare): Direct competitor in AI-guided cardiac ultrasound acquisition, originally founded to enable novice users to capture diagnostic-quality echocardiograms. Acquired by GE HealthCare in 2023, embedding the technology into a major incumbent's ultrasound portfolio — UltraSight's most direct substitute.
Broad incumbents
- GE HealthCare: Largest ultrasound incumbent with deep cardiology installed base and the Caption Health AI acquisition. Bundles hardware, AI, and enterprise cardiology workflows at scale that UltraSight must match or partner around.
- Philips: Major ultrasound incumbent and UltraSight partner (Lumify integration). Owns AI ultrasound development capabilities and vast cardiology distribution — represents both the largest commercial opportunity and the most significant competitive threat.
Emerging players
- Dia Imaging Analysis: AI-powered cardiac ultrasound analysis company focused on automated quantification of echo parameters. Adjacent to UltraSight in the cardiac AI workflow — interpretation layer complementing UltraSight's acquisition layer.
- Eko Health: AI-augmented cardiac auscultation (digital stethoscope) company pursuing FDA-cleared AI for cardiac disease detection. Adjacent point-of-care cardiology AI for primary/ambulatory use — potential upstream or downstream complement to UltraSight's imaging workflow.
- HeartVista: Cardiac MRI AI company enabling faster scan acquisition through automated guidance. Targets cardiology AI in a different modality but with parallel workflow philosophy and overlapping customer base in academic cardiology.
- Intelligent Ultrasound: AI ultrasound simulation and guidance company, publicly traded on AIM. Addresses similar novice-user enablement for ultrasound acquisition with broader (non-cardiac) clinical scope, representing adjacent competition for hospital training budgets.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
UltraSight social profiles
Digital presenceUltraSight compliance and trust
Trust signalCompliance7 records
UltraSight financial estimates
Financial estimateRevenue estimate
Valuation estimate
UltraSight leadership team
Management profileNumber of profiles
Profiles13 records
UltraSight subsidiaries and ownership
Company hierarchySubsidiaries1 record
UltraSight funding detail
Funding detailFunding overview
Funding rounds5 records
Investors12 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
UltraSight M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about UltraSight
What does UltraSight do?
UltraSight develops AI-powered real-time guidance software that enables healthcare professionals without prior sonography experience to acquire diagnostic-quality cardiac ultrasound images at the point of care. The software analyzes the ultrasound video stream using geometric deep learning, predicts probe position relative to the heart, and provides 3D graphical guidance on probe maneuvering along with automated image quality assessment. It is designed as an accessory that pairs with compatible point-of-care ultrasound devices from partners such as Philips, Butterfly Network, and EchoNous, and is licensed to healthcare systems, hospitals, and OEMs worldwide.
Is UltraSight a public or private company?
UltraSight is a private company. It is classified as venture growth investor backed and is currently operating.
When was UltraSight founded?
UltraSight was founded in 2018. It employs 11 to 50 people.
Where is UltraSight based?
UltraSight is headquartered in Rehovot, Israel, in the Middle East region.
How does UltraSight make money?
Two revenue lines are on record. AI-Guided Cardiac Ultrasound Software License is the primary driver. The others are joint Venture Revenue - Asia Pacific.
Who are UltraSight's main competitors?
Direct peers on record are Butterfly Network, Ultromics, EchoNous and Caption Health (GE HealthCare). Broad incumbents are GE HealthCare and Philips. Emerging players are Dia Imaging Analysis, Eko Health, HeartVista and Intelligent Ultrasound.
Does UltraSight have an API?
No public API is recorded for UltraSight.
What industry is UltraSight in?
UltraSight's product category is AI Cardiac Ultrasound Software. Its primary akta.pro industry code is HLAHABAJ, Radiology AI, CAD & Advanced Visualization Software, with a secondary code of HDAAAEAH, Medical Imaging AI. Its NAICS code is 334510 and its SIC code is 3841.